

NEW PRODUCTS

by Megan Silveira, assistant editor

Healthy Headway

This month's newest products focus on preventing or treating health issues in the herd.

Baytril 100-CA1 (enrofloxacin) injectable solution

The FDA Center for Veterinary Medicine granted Bayer Animal Health a conditional approval for Baytril® 100-CA1 (enrofloxacin) injectable solution for the treatment of clinical anaplasmosis in cattle. Veterinarians and cattle producers can expect to see this product on the shelf in May 2020.

“Options to address clinical anaplasmosis in cattle have been limited,” says Sebastian Kuszmierczyk, head of farm animal products in the United States for Bayer Animal Health. “This conditional approval allows us to offer the proven efficacy of enrofloxacin as a new treatment for this potentially deadly disease.”

Usually spread by ticks, bovine anaplasmosis is a vector-borne infectious blood disease. While feeding the tick transmits bacteria. The bacteria infect the animal's red blood cells and cause severe anemia.

Anaplasmosis can be extremely difficult to detect, as animals can be carriers of the disease without exhibiting any symptoms. The disease is most devastating in females at least three years of age. Younger animals often do not show signs of infection but become carriers.

Animals can carry the bacteria their entire lives.

Infected cattle exhibit signs of weakness, weight loss, aggression, constipation, high fever and decreased appetite.

This new treatment option is indicated for treatment of all classes of beef cattle excluding calves less than two months of age and bulls intended for breeding. Baytril 100-CA1 is conditionally approved pending a full demonstration of the solution's effectiveness.

For more information visit www.bayerlivestock.com.

Pinkeye vaccine portfolio

In March, Merck Animal Health announced an agreement with Addison Biological Laboratory, Inc. to market *Moraxella Bovoculi* Bacterin. This product is the only vaccine commercially available for the prevention of pinkeye in cattle.

Pinkeye — Infectious Bovine Keratoconjunctivitis (IBK) — is highly contagious and can be costly for cattle producers. Pinkeye is estimated to create losses of more than \$150 million annually in the United States.

Moraxella bovis was the bacteria always known to be responsible for pinkeye, but recent years have shed

light on *M. bovoculi*, bacteria often found in winter cases of pinkeye.

“Options to help prevent *M. bovoculi* have been limited, so we are pleased to provide bovine veterinarians and producers with this vaccine,” says Tim Parks, ruminant technical services manager for Merck Animal Health. “*Moraxella Bovoculi* Bacterin includes eight different *M. bovoculi* isolates — and when used in conjunction with Vision® or Piliguard® vaccines for *M. bovis* — provides comprehensive pinkeye protection.”

While pinkeye is commonly thought of as being a common infection in the summertime, it can occur year-round. *Moraxella Bovoculi* Bacterin is an addition to the Merck Animal Health pinkeye portfolio that includes vaccines offering protection against *M. bovis*, namely 20/20 Vision 7 with SPUR™, Piliguard Pinkeye-1 Trivalent and Piliguard Pinkeye+7.

For more information visit www.mahcattle.com. 